Singapore
Search
Sign In
Endocrinology
Top Medical News
A diet rich in cholesterol during early pregnancy and genetic variations of cholesterol metabolism genes both contribute to the risk of gestational diabetes mellitus (GDM), suggests a study.
Plasma alanine or factors affecting alanine appear to contribute to an increased risk of diabetes, higher blood glucose, low-density lipoprotein cholesterol (LDL-C), and blood pressure (BP), but not coronary artery disease (CAD), reports a study.
Very high levels of high-density lipoprotein cholesterol (HDL-C) appear to contribute to increased risk of developing dementia among healthy older adults, as reported in a study.
A cardiovascular disease (CVD) risk reduction intervention, the Strong Hearts, Healthy Communities 2.0 (SHHC-2.0), may be useful among midlife and older female adults of rural communities in improving their diet patterns and diet-related psychosocial wellbeing consistent with improved cardiovascular health, according to a study.
Asians with extremely high or low fat mass index (FMI) and fat-free mass index (FFMI) are at increased risk of mortality, suggests a study. However, the associations of FMI and FFMI with the mortality risk differ across subgroups and causes of death.
Individuals with type 2 diabetes (T2D) who have high blood pressure (BP) levels are at increased risk of death from cardiovascular disease (CVD), according to a large registry cohort in Singapore. However, the risk increase is also present for those who have low diastolic BP.
Special Reports
Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.
Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Metabolic Syndrome (MS) is linked to insulin resistance and a combination of five medical conditions that increase the risk of developing atherosclerotic cardiovascular disease (ASCVD). Obesity is independently associated with an increased incidence of diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease (CVD), and certain cancers. Early CVD protection is crucial in MS patients with Type 2 diabetes (T2DM). The use of empagliflozin/metformin for managing T2DM in MS improved fasting blood glucose levels and HbA1c, demonstrating the effectiveness of this combination in both ASCVD and CVD risk factors patients.
Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.
Professor Bertrand Tombal
Professor of Urology
Cliniques universitaires Saint-Luc & Université catholique de Louvain
Brussels, Belgium
Associate Professor Edmund Chiong
Head, Department of Urology
National University Hospital, Singapore
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Conference Reports
Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.
Once weekly treatment with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide significantly reduced HbA1c level and body weight in a large cohort of adults with type 2 diabetes (T2D) in a real-world study from Israel.
Treatment with bimagrumab appears to prevent muscle loss resulting from inadequate protein intake and increase muscle mass in the setting of enough protein intake, according to data from phase I and IIa studies.
Treatment with faster-acting insulin aspart in pregnant women with diabetes appears to have no adverse effect on foetal growth and even leads to fewer episodes of hypoglycaemia, according to the Copenfast trial.
A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.
Multimedia
